Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0293)
Name
Quisinostat
Synonyms
QUISINOSTAT; 875320-29-9; JNJ-26481585; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; JNJ26481585; JNJ 26481585; N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide; 9BJ85K1J8S; Quisinostat (JNJ-26481585); 5-Pyrimidinecarboxamide, N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)-1-piperidinyl)-; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide; 2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]-~{N}-oxidanyl-pyrimidine-5-carboxamide; Quisinostat [USAN]; Quisinostat [USAN:INN]; UNII-9BJ85K1J8S; GOK; N-Hydroxy-2-[4-({[(1-methyl-1H-indol-3-yl)methyl]amino}methyl)piperidin-1-yl]pyrimidine-5-carboxamide; QUISINOSTAT [INN]; Quisinostat (USAN/INN); QUISINOSTAT [WHO-DD]; MLS006011096; GTPL7503; SCHEMBL2360460; CHEMBL2105763; CHEBI:94771; DTXSID90236376; JNJ 26481585 dihydrochloride; HMS3654M19; HMS3747E21; BCP01811; BDBM50105327; MFCD17010272; NSC759657; AKOS016004011; BCP9000803; CS-5065; DB12985; NSC-759657; SB16528; NCGC00346487-01; NCGC00346487-04; AC-27415; AS-16361; HY-15433; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamid; N-hydroxy-2-(4-(((1-methyl-1H-indol-3-yl)methylamino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; SMR004702884; FT-0700499; SW219796-1; EC-000.2337; D10321; A862539; Q7272620; BRD-K83837640-001-01-4; N-hydroxy-2-(4-(((1-methyl-1H-indol-3-yl)methylamino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide dihydrochloride; N-Hydroxy-2-[4-[[[(1-methyl-1H-indol-3-yl)methyl]amino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide

    Click to Show/Hide
Structure
Formula
C21H26N6O2
IUPAC Name
N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide
Canonical SMILES
CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO
InChI
InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
InChIKey
PAWIYAYFNXQGAP-UHFFFAOYSA-N
PubChem CID
11538455
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Oral squamous cell carcinoma ICD-11: 2B6E
 Disease Info 
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Necroptosis hsa04217
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
Cell pyroptosis
In Vitro Model CAL-27 cells Tongue adenosquamous carcinom Homo sapiens CVCL_1107
Tca8113 cells Endocervical adenocarcinoma Homo sapiens CVCL_6851
In Vivo Model
Adult male athymic BALB/c nude mice (20-22 g of 5-week-old mice) were housed in a controlled environment at 23 ± 2 and 40%-70% humidity under a 12 h dark/light cycle with free access to irradiated food and sterile water. A suspension of 6 x 106/100 uL TCA-8113 cells was inoculated subcutaneously into the hind flank region of each nude mouse. The average tumor volume in nude mice reached 100 mm3, and mice were randomly divided into three groups. Quisinostat was formulated in normal saline and administered at 3 and 10 mg/kg/day byintraperitoneal injection. Control mice were given equal volume saline intraperitoneally. The tumor volume and the bodyweight of mice were monitored every three days.

    Click to Show/Hide
Response regulation Quisinostat could increase the apoptosis rate in the tumor tissues of nude mice. Up-regulation of the expression of p53 and down-regulated expression of GPX4 in cell lines were observed by immunofluorescent staining, and the expression locations of p53 and GPX4 proteins in TSCC cells were observed. Quisinostat may be a potential drug for the treatment of tongue squamous cell carcinoma.
References
Ref 1 Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis. Toxicol Appl Pharmacol. 2021 Jan 1;410:115363. doi: 10.1016/j.taap.2020.115363. Epub 2020 Dec 5.